NMRA

Neumora Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.50
52-Week Range: $0.47 – $3.65
Market Cap: $98.70M
P/E (TTM): —
EPS (TTM): -1.23
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.21
PEG Ratio: —
Return on Equity: -187.11%
Return on Assets: -73.85%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.50
Debt/Equity: 1.20
Total Debt: $53.25M
Free Cash Flow: $-99.42M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $30.35M

NMRA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$104.75M	$206.62M	$200.93M	$181.06M
Selling, General & Admin	$31.12M	$45.48M	$62.54M	$60.09M
Operating Expenses	$135.87M	$252.10M	$263.46M	$241.16M
Operating Income	-$135.87M	-$252.10M	-$263.46M	-$241.16M
EBITDA	-$135.28M	-$251.43M	-$262.83M	-$233.37M
Pretax Income	-$130.90M	-$235.66M	-$243.61M	-$236.80M
Income Tax	$0.00	$268.00K	$178.00K	$130.00K
Net Income	-$130.90M	-$235.93M	-$243.79M	-$236.93M
Diluted EPS	-0.86	-3.63	-1.53	-1.45
Diluted Shares	151.95M	65.02M	159.38M	163.39M

NMRA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$240.94M	$374.04M	$142.15M	$182.53M
Receivables	$919.00K	$939.00K	—	—
Current Assets	$387.95M	$478.28M	$314.06M	$190.54M
Total Assets	$426.23M	$496.19M	$316.97M	$191.05M
Current Liabilities	$23.70M	$25.11M	$29.89M	$32.45M
Long-Term Debt	—	—	—	$54.53M
Total Debt	$8.44M	$5.23M	$1.85M	$55.01M
Total Liabilities	$873.08M	$27.12M	$29.91M	$87.18M
Retained Earnings	-$467.51M	-$703.43M	-$947.22M	-$1.18B
Shareholders' Equity	-$446.85M	$469.08M	$287.06M	$103.87M
Working Capital	$364.26M	$453.17M	$284.17M	$158.09M

NMRA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$114.90M	-$163.28M	-$182.94M	-$206.44M
Capital Expenditure	-$511.00K	-$117.00K	—	—
Free Cash Flow	-$115.41M	-$163.40M	-$182.94M	-$206.44M
Depreciation & Amortisation	$594.00K	$668.00K	$631.00K	$208.00K
Stock-Based Compensation	$8.30M	$17.24M	$39.99M	$29.88M
Investing Cash Flow	-$168.01M	$64.39M	-$70.56M	$168.52M
Financing Cash Flow	$115.74M	$231.94M	$21.60M	$77.09M
Share Repurchases	$0.00	-$491.00K	$0.00	—
Net Change in Cash	-$167.17M	$133.04M	-$231.89M	$39.17M

NMRA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$52.15M	$38.72M	$45.52M	$44.67M	$38.60M	$29.28M
Selling, General & Admin	$18.79M	$15.32M	$12.18M	$13.81M	$14.27M	$12.91M
Operating Expenses	$70.94M	$54.04M	$57.70M	$58.48M	$52.86M	$42.19M
Operating Income	-$70.94M	-$54.04M	-$57.70M	-$58.48M	-$52.86M	-$42.19M
EBITDA	-$67.73M	-$52.25M	-$55.98M	-$57.41M	-$51.57M	-$41.26M
Pretax Income	-$67.89M	-$52.71M	-$56.76M	-$59.45M	-$53.43M	-$43.08M
Income Tax	$105.00K	$25.00K	$0.00	$0.00	$30.00K	$0.00
Net Income	-$67.99M	-$52.73M	-$56.76M	-$59.45M	-$53.46M	-$43.08M
Diluted EPS	-0.42	-0.33	-0.35	-0.35	-0.30	-0.23
Diluted Shares	161.45M	161.69M	161.84M	168.52M	179.87M	185.16M

NMRA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$126.86M	$124.52M	$129.07M	$182.53M	$147.07M	$116.83M
Current Assets	$254.87M	$222.91M	$177.08M	$190.54M	$153.43M	$124.87M
Total Assets	$256.75M	$223.82M	$177.83M	$191.05M	$153.88M	$125.25M
Current Liabilities	$28.38M	$21.16M	$25.84M	$32.45M	$30.11M	$27.78M
Long-Term Debt	—	$19.45M	$19.56M	$54.53M	$52.96M	$52.91M
Total Debt	$938.00K	$19.96M	$20.09M	$55.01M	$53.37M	$53.25M
Total Liabilities	$28.38M	$40.95M	$45.67M	$87.18M	$83.20M	$80.73M
Retained Earnings	-$1.02B	-$1.07B	-$1.12B	-$1.18B	-$1.24B	-$1.28B
Shareholders' Equity	$228.36M	$182.88M	$132.16M	$103.87M	$70.68M	$44.52M
Working Capital	$226.48M	$201.75M	$151.24M	$158.09M	$123.32M	$97.10M

NMRA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$59.45M	-$52.40M	-$46.63M	-$47.95M	-$46.40M	-$39.53M
Free Cash Flow	-$59.45M	-$52.40M	-$46.65M	-$47.94M	-$46.40M	-$39.53M
Depreciation & Amortisation	$157.00K	$19.00K	$23.00K	$9.00K	$8.00K	$7.00K
Stock-Based Compensation	$9.32M	$7.17M	$5.98M	$7.41M	$7.41M	$7.18M
Investing Cash Flow	$44.16M	$30.40M	$51.32M	$42.65M	$71.00K	$0.00
Financing Cash Flow	$0.00	$18.46M	-$136.00K	$58.77M	$10.88M	$9.29M
Net Change in Cash	-$15.29M	-$3.55M	$4.55M	$53.46M	-$35.46M	-$30.24M

Market Snapshot

About

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain diseases. The company uses precision medicine approaches and biomarker-driven strategies to address neuropsychiatric and neurodegenerative disorders.